Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC)’s share price fell 4.2% during mid-day trading on Monday . The stock traded as low as $0.46 and last traded at $0.46. 926,694 shares were traded during mid-day trading, a decline of 31% from the average session volume of 1,344,399 shares. The stock had previously closed at $0.48.

Several research firms have recently issued reports on NVCN. ValuEngine lowered Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Zacks Investment Research lowered Neovasc Inc (US) from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $1.05 target price on shares of Neovasc Inc (US) in a report on Friday, January 19th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $2.95.

The company has a market cap of $36.06, a price-to-earnings ratio of 1.69 and a beta of -0.24.

Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last released its earnings results on Tuesday, November 14th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a net margin of 268.35% and a negative return on equity of 85.81%. research analysts predict that Neovasc Inc will post -0.21 EPS for the current fiscal year.

An institutional investor recently raised its position in Neovasc Inc (US) stock. Capital World Investors increased its holdings in Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) by 9.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,294,667 shares of the medical equipment provider’s stock after acquiring an additional 522,864 shares during the period. Capital World Investors owned about 7.98% of Neovasc Inc (US) worth $8,737,000 at the end of the most recent quarter. Institutional investors own 19.03% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at

Neovasc Inc (US) Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.